Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
7.32 USD +0.41% Intraday chart for TScan Therapeutics, Inc. +7.33% +25.56%
04-19 TScan Therapeutics Closes $150.1 Million Securities Offering MT
04-17 TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
GL
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
GL
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
GL
TScan Therapeutics Announces Closing of Upsized Public Offering
AQ
TScan Therapeutics Closes $150.1 Million Securities Offering
MT
TScan Therapeutics Announces Closing of Upsized Public Offering
GL
TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants
MT
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
GL
TScan Therapeutics Launches $125 Million Securities Offering; Shares Rise After Hours
MT
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
GL
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
GL
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities
CI
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
GL
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
AQ
TScan Therapeutics, Inc. Announces Executive Changes
CI
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
GL
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Barclays Raises Price Target on TScan Therapeutics to $9 From $7, Keeps Overweight Rating
MT
TScan Therapeutics Files $300 Million Mixed-Securities Shelf
MT
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TCRX Stock
  4. News TScan Therapeutics, Inc.